SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal ...
News-Medical.Net on MSN5d
New hepatitis B vaccine outperforms standard boosters in health care workersHealth care workers are at higher risk of hepatitis B infection due to occupational exposure to blood and body fluids.
SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal ...
Sinovac is recognized for its research and development, manufacturing, and commercialization of vaccines for infectious diseases, including COVID-19, hepatitis A, and influenza, among others.
SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, ...
BEIJING, March 28, 2025--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback